Protagonist Therapeutics Inc banner

Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 105.98 USD 2.17% Market Closed
Market Cap: $6.8B

Protagonist Therapeutics Inc
Total Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Protagonist Therapeutics Inc
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Protagonist Therapeutics Inc
NASDAQ:PTGX
Total Receivables
$4.5m
CAGR 3-Years
256%
CAGR 5-Years
5%
CAGR 10-Years
20%
Abbvie Inc
NYSE:ABBV
Total Receivables
$12.6B
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Total Receivables
$4.9B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Total Receivables
$9.6B
CAGR 3-Years
20%
CAGR 5-Years
16%
CAGR 10-Years
12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Receivables
$2.1B
CAGR 3-Years
12%
CAGR 5-Years
18%
CAGR 10-Years
28%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Receivables
$5.7B
CAGR 3-Years
3%
CAGR 5-Years
7%
CAGR 10-Years
15%
No Stocks Found

Protagonist Therapeutics Inc
Glance View

Market Cap
6.8B USD
Industry
Biotechnology

Protagonist Therapeutics Inc. stands as a pioneering player in the biopharmaceutical landscape, diligently orchestrating the journey from scientific discovery to therapeutic breakthroughs. Established with the vision to exploit the therapeutic potential of peptides, the company has carved a niche for itself by focusing on innovative peptide-based drug discovery and development. Their proprietary technology platform is designed to genetically engineer and optimize peptides aimed at treating a spectrum of diseases, notably in areas of unmet medical needs such as autoimmune conditions and rare genetic disorders. The fusion of cutting-edge biotechnology and seasoned expertise enables Protagonist to transform promising scientific concepts into viable medicines, paving the way for advancements in patient treatment options. Fueling its growth and revenue potential, Protagonist Therapeutics operates primarily through partnerships and collaborative alliances, as well as progressing its proprietary pipeline. By leveraging strategic collaborations with established pharmaceutical giants, the company garners funding, technological insights, and broader developmental capabilities. This collaborative synergy not only bolsters their research endeavors but also hastens the clinical development and eventual commercialization of their pipeline products. Their ability to secure partnerships and effectively progress their drug candidates through various clinical stages is critical to their financial model, converting scientific innovation into shareholder value and societal impact. The company continues to navigate the complexities of drug development with a steadfast focus on unlocking the therapeutic potential of peptides, aspiring to merge innovation with tangible health benefits.

PTGX Intrinsic Value
12.83 USD
Overvaluation 88%
Intrinsic Value
Price $105.98

See Also

What is Protagonist Therapeutics Inc's Total Receivables?
Total Receivables
4.5m USD

Based on the financial report for Dec 31, 2025, Protagonist Therapeutics Inc's Total Receivables amounts to 4.5m USD.

What is Protagonist Therapeutics Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
20%

Over the last year, the Total Receivables growth was -97%. The average annual Total Receivables growth rates for Protagonist Therapeutics Inc have been 256% over the past three years , 5% over the past five years , and 20% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett